ENHANCING VACCINAL PREVENTION OF THE HUMAN PAPILLOMA VIRAL (HPV) INFECTION: PROTECTING PEOPLE OF DIFFERENT AGE AND SEX FROM A RANGE OF HPV-ASSOCIATED DISEASES
https://doi.org/10.15690/pf.v10i1.584
Abstract
HPV is the most widespread sexually transmitted infection. HPV affects men and women regardless of age and leads to the development of various anogenital area diseases. International studies proved a wide clinical range of the tetravalent HPV vaccine protection and allowed recommending it for the prevention of not only cervical cancer, but also of vulvar, vaginal and anal cancer and anogenital condylomae in patients of both sexes. 42 countries have already introduced national HPV-vaccination programs in compliance with WHO recommendations. Anogenital area cancer morbidity reduction in these countries is expected in 10-15 years. However, a reduction or even complete disappearance of anogenital condylomae among the population has already been noted in a range of countries because the incubation period of this disease is short; this is the first marker of vaccination efficacy in a population.
About the Authors
M. G. Galitskaya
Scientific Center of Children’s Health, Moscow, Russian Federation
MD, head of the vaccinal prevention department for children with medical issues at the FSBI RAMS “SCCH”
MD, head of the vaccinal prevention department for children with medical issues at the FSBI RAMS “SCCH”
A. G. Gayvoronskaya
Scientific Center of Children’s Health, Moscow, Russian Federation
References
1. Munoz N., Castellsague X., Bosch F.X., Tafur L., de Sanjose S., Aristizabal N., Ghaffari A.M., Shah K.V. Difficulty in elucidating the male role in cervical cancer in Colombia, a high-risk area for the disease. J. Natl. Cancer Inst. 1996; 88 (15): 1068–75.
2. Castellsague X., Ghaffari A., Daniel R. W., Bosch F. X., Munoz N., Shah K. V. Prevalence of penile human papillomavirus DNA in husbands of women with and without cervical neoplasia: a study in Spain and Colombia. J. Infect. Dis. 1997; 176 (2): 353–61.
3. Burd E. M. Clin. Microbiol. Rev. 2003; 16: 1–17.
4. Bosch F. X., Burchell A. N., Schiffman M., Giuliano A. R. et al. Epidemiology and natural history of human papillomavirus infections and typespecific implications in cervical neoplasia. Vaccine. 2008; 26S: K1–K16.
5. Brown D. R. et al. J. Clin. Microbiol. 1999; 37: 3316–3322.
6. Koutsky L. Am. J. Med. 1997; 102: 3–8.
7.
8.
Review
For citations:
Galitskaya M.G., Gayvoronskaya A.G. ENHANCING VACCINAL PREVENTION OF THE HUMAN PAPILLOMA VIRAL (HPV) INFECTION: PROTECTING PEOPLE OF DIFFERENT AGE AND SEX FROM A RANGE OF HPV-ASSOCIATED DISEASES. Pediatric pharmacology. 2013;10(1):13-17. https://doi.org/10.15690/pf.v10i1.584
Views:
877
Email this article 